Nemaura Medical to Conduct Shareholder Update Call April 28, 2021, 4:30PM ET
Nemaura Medical (NASDAQ: NMRD) will conduct a shareholder update call on April 28, 2021, at 4:30 PM ET. Participants need to pre-register to attend. The call will address pre-submitted questions, with dial-in options available for those without internet access. Nemaura develops non-invasive wearable diagnostic devices, including sugarBEAT®, a glucose monitor, and proBEAT™, launched as a general wellness product. The company is positioned in the rapidly growing diabetes and health-tech markets.
- Development of non-invasive wearable diagnostic devices, targeting significant diabetes markets.
- Commercialization of sugarBEAT®, a CE-mark approved continuous glucose monitor.
- ProBEAT™ launched in the U.S. for general wellness applications, enhancing product portfolio.
- Risks related to regulatory status and potential FDA re-evaluation of product classifications.
- Uncertainties regarding the success of new product launches and commercial partnerships.
Loughborough, England, April 21, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced will host a shareholder update call on Wednesday, April 28, 2021 at 4:30 pm ET.
Participants are asked to pre-register for the call through the following link: https://dpregister.com/sreg/10154964/e6da9faa78.
Please note that registered participants will receive their dial in number upon registration and will dial directly into the call without delay. Those without Internet access or unable to pre-register may dial in by calling: 1-866-777-2509 (U.S. domestic), 1-412-317-5413 (international) or 0203 5143188 (United Kingdom, toll free). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Nemaura Medical call.
The conference call will also be available through a live webcast found here.
A telephonic replay of the call will be available through May 6, 2021 and may be accessed by calling 1-877-344-7529 (U.S. domestic) or 1-412-317-0088 (international) and using access code 10154964.
Although there will be no live Q&A session, management will address pre-submitted questions during the call. Those wishing to submit a question may do so via brets@coreir.com using the subject line “Conference Call Question Submission.”
About Nemaura Medical, Inc.
Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT®diabetes program.
The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly
For more information, please visit www.NemauraMedical.com.
Cautionary Statement Regarding Forward-Looking Statements:
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, the launch of proBEAT™ in the US, risks related to regulatory status and the failure of future development and preliminary marketing efforts, Nemaura’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Nemaura and its partners’ ability to develop, market and sell proBEAT™, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to both proBEAT™ digital health, and sugarBEAT®. There can be no assurance that the company will be able to reach a part of or any of the global market for CGM with its products/services. The FDA reserves the right to re-evaluate their decision that proBEAT™ qualifies as a general wellness product should it become aware of any issues such as skin irritation or other adverse events from the device, as well as any misuse impacting patient safety, and any other reason as the FDA may see fit at its discretion to determine the product does not fit the definition of a general wellness product. These and other risks and uncertainties are identified and described in more detail in Nemaura’s filings with the United States Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the most recently completed fiscal year, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Nemaura undertakes no obligation to publicly update or revise any forward-looking statements.
Contact:
Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com
FAQ
What date is Nemaura Medical's shareholder update call?
How can I participate in Nemaura Medical's update call?
What products does Nemaura Medical focus on?
What markets is Nemaura Medical operating in?
What are the potential risks for Nemaura Medical's products?
